Changes of Tear-film Lipid Layer Thickness and Ocular Aberration After Treatment of Meibomian Gland Dysfunction
Overview
- Phase
- Not Applicable
- Intervention
- Treatment of Meibomian gland dysfunction
- Conditions
- Meibomian Gland Dysfunction
- Sponsor
- Yonsei University
- Enrollment
- 45
- Locations
- 1
- Primary Endpoint
- Changes of tear-film lipid layer thickness after treatment of meibomian gland dysfunction
- Status
- Completed
- Last Updated
- 7 years ago
Overview
Brief Summary
In this study, investigator aim to evaluate the changes of tear-film lipid layer thickness and ocular aberration after treatment of meibomian gland dysfunction. In case of stage 3 or 4 meibomian gland dysfunction, participants will be treated using conventional treatment modalities. Before treatment and after 1 and 2 months of treatment, a variety of ophthalmic examination, tear-film lipid layer thickness, and ocular aberration are going to measured and compared.
Investigators
Eligibility Criteria
Inclusion Criteria
- •age over 19 years old, with moderate to severe Meibomian gland dysfunction.
Exclusion Criteria
- •patients with history of previous ocular or intraocular surgery
- •ocular infection, non dry eye ocular inflammation, ocular allergy, autoimmune disease
- •history of intolerance or hypersensitivity to any component of the study medications
- •wearing contact lenses during the study period, presence of current punctal occlusion
- •pregnancy, lactating women, and children
Arms & Interventions
moderate to severe meibomian gland dysfunction
Intervention: Treatment of Meibomian gland dysfunction
Outcomes
Primary Outcomes
Changes of tear-film lipid layer thickness after treatment of meibomian gland dysfunction
Time Frame: 1 and 2 months after treatment of meibomian gland dysfunction
Changes of ocular aberration after treatment of meibomian gland dysfunction
Time Frame: 1 and 2 months after treatment of meibomian gland dysfunction
ocular parameters measured by Ray-tracing wavefront aberrometers (i-Trace, Tracey technologies , Texas ,USA)
Secondary Outcomes
- Meibomian quality(1 and 2 months after treatment of meibomian gland dysfunction)
- Meibomian gland abnormality(1 and 2 months after treatment of meibomian gland dysfunction)
- Corneal erosion grade(oxford score)(1 and 2 months after treatment of meibomian gland dysfunction)
- OSDI(ocular surface disease index)(1 and 2 months after treatment of meibomian gland dysfunction)
- BUT(tear break-up time)(1 and 2 months after treatment of meibomian gland dysfunction)